Incyte Ends Jakafi Pancreatic Cancer Trials, But Has More Irons In The Fire

Pancreatic trial failure means the end of the inflammation hypothesis for Jakafi and thus the end of related solid tumor trials, but trials of JAK inhibitors in other solid tumors still have potential, says Incyte.